This recombinant monoclonal antibody is designed as a research-grade biosimilar to Depemokimab, targeting interleukin-5 (IL-5), a key cytokine in eosinophil biology. IL-5 plays a central role in the differentiation, maturation, activation, and survival of eosinophils, a type of white blood cell involved in allergic and inflammatory responses. Elevated IL-5 levels and eosinophilia are associated with several respiratory conditions including severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and hypereosinophilic syndrome. By binding to IL-5, this antibody prevents the cytokine from interacting with its receptor on eosinophil surfaces, thereby inhibiting eosinophil-mediated inflammatory processes.
Depemokimab is an investigational long-acting monoclonal antibody developed for the treatment of eosinophilic disorders and has shown promise in clinical trials for severe asthma management. This biosimilar antibody serves as a valuable research tool for investigating IL-5-mediated pathways, eosinophil biology, and the pathophysiology of eosinophilic diseases. It enables researchers to explore therapeutic mechanisms and conduct preclinical studies in immunology and respiratory disease models.
Email: support@cusabio.com
Distributors Worldwide